CCL2 and triple-A syndrome: Besides, empagliflozin diminished elastin degradation, neovessel formation, macrophage infiltration and expression of CCL-2 [chemokine (C-C motif) ligand 2] and CCL-5 [chemokine (C-C motif) ligand 5], VEGF (vascular endothelial growth factor), MMP-2 and MMP-9 at the AAA lesion.